Last reviewed · How we verify

Rifampin, isoniazid, pyrazinamide, ethambutol — Competitive Intelligence Brief

Rifampin, isoniazid, pyrazinamide, ethambutol (Rifampin, isoniazid, pyrazinamide, ethambutol) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-tuberculosis agent (fixed-dose combination). Area: Infectious Disease.

marketed Anti-tuberculosis agent (fixed-dose combination) Multiple: RNA polymerase (rifampin), mycolic acid synthesis (isoniazid), arabinosyl transferases (ethambutol), pyrazinamidase/nicotinamidase (pyrazinamide) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Rifampin, isoniazid, pyrazinamide, ethambutol (Rifampin, isoniazid, pyrazinamide, ethambutol) — ANRS, Emerging Infectious Diseases. This is a fixed-dose combination of four first-line anti-tuberculosis drugs that work synergistically to inhibit bacterial cell wall synthesis and mycolic acid production, killing Mycobacterium tuberculosis.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Rifampin, isoniazid, pyrazinamide, ethambutol TARGET Rifampin, isoniazid, pyrazinamide, ethambutol ANRS, Emerging Infectious Diseases marketed Anti-tuberculosis agent (fixed-dose combination) Multiple: RNA polymerase (rifampin), mycolic acid synthesis (isoniazid), arabinosyl transferases (ethambutol), pyrazinamidase/nicotinamidase (pyrazinamide)
HR HR Global Alliance for TB Drug Development marketed Anti-tuberculosis agent (fixed-dose combination) Mycobacterial cell wall (isoniazid) and bacterial RNA polymerase (rifampicin)
Rifampin/isoniazid/pyrazinamide/ethambutol FDC Rifampin/isoniazid/pyrazinamide/ethambutol FDC Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections marketed Anti-tuberculosis agent (fixed-dose combination) Bacterial RNA polymerase (rifampin), mycolic acid synthesis (isoniazid), membrane potential/energy metabolism (pyrazinamide), arabinosyl transferase (ethambutol)
Rifampicin, Pyrazinamide, Ethambutol and Isoniazid Rifampicin, Pyrazinamide, Ethambutol and Isoniazid University of Cape Town phase 3 Anti-tuberculosis agent (fixed-dose combination) Bacterial RNA polymerase (rifampicin), mycolic acid synthesis (isoniazid), cellular metabolism (pyrazinamide), arabinosyl transferase (ethambutol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-tuberculosis agent (fixed-dose combination) class)

  1. ANRS, Emerging Infectious Diseases · 1 drug in this class
  2. Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 1 drug in this class
  3. Global Alliance for TB Drug Development · 1 drug in this class
  4. University of Cape Town · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rifampin, isoniazid, pyrazinamide, ethambutol — Competitive Intelligence Brief. https://druglandscape.com/ci/rifampin-isoniazid-pyrazinamide-ethambutol. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: